application): The applicants propose to exploit the metal-siderophore transport systems in bacteria to develop a new class of antibiotics. In particular, aerobactin and other siderophores have been shown to sequester essential metals, such as iron in bacteria. This process does not occur in mammalian cells. The applicants will evaluate the potential of these molecules and related analogues to transport toxic metals into the host bacteria. In addition, the applicants will utilize proprietary technology to prepare combinatorial libraries of aerobactin and related siderophores.

Proposed Commercial Applications

With the increasing frequency of bacterial strains that show resistance to all currently available antibiotics, there is a compelling need in the market for effective therapeutic options. This study will determine the feasibility of a new class of antibiotics which have a modality of action different from known drugs, and could result in a commercially successful drug.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI043730-01
Application #
2712415
Study Section
Special Emphasis Panel (ZRG3-SSS-Z (01))
Project Start
1998-06-15
Project End
1999-01-14
Budget Start
1998-06-15
Budget End
1999-01-14
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Metaphore Pharmaceuticals, Inc.
Department
Type
DUNS #
City
St. Louis
State
MO
Country
United States
Zip Code
63114